Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Johnson & Johnson (NY:JNJ)

153.25 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Apr 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Johnson & Johnson

< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
J&J Retail Traders Unfazed By Court Rejecting 3rd Talc Settlement, But Analyst Sees Stock Pullback Risk
According to Bloomberg, a monthly prescription of Zepbound via Hims' platform would cost $1,899 — $800 more than Lilly's list price for the drug. 
Via Stocktwits
Topics Bankruptcy Lawsuit
Exposures Financial Legal
Newsmax, Waton Financial, Johnson & Johnson, Hims & Hers Health, Tesla: Why These 5 Stocks Are On Investors' Radars Today
U.S. stocks closed higher on Tuesday, with the Nasdaq Composite climbing 0.9% to 17,449.89. The S&P 500 added nearly 0.4%, finishing at 5,633.07. 
Via Benzinga
Topics Stocks
Exposures US Equities
Uncover the latest developments among S&P500 stocks in today's session.
Curious about the S&P500 stocks that are in motion on Tuesday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
Johnson & Johnson Stock Is Tumbling Tuesday: What Going On?
Johnson & Johnson Inc. (NYSE: JNJ) shares are trading lower Tuesday after a U.S. bankruptcy court in Texas rejected subsidiary Red River Talc's request to approve its prepackaged bankruptcy plan. 
Via Benzinga
Topics Bankruptcy
Exposures Financial Legal
Why Johnson & Johnson Stock Is Sinking Today
Via The Motley Fool
Topics Bankruptcy Lawsuit Stocks
Exposures Financial Legal US Equities
Exploring the top movers within the S&P500 index during today's session.
Wondering what's happening in today's session for the S&P500 index? Stay informed with the top movers within the S&P500 index on Tuesday. 
Via Chartmill
Stocks Edge Higher Despite Trade, Economic Jitters
Stocks are modestly higher Tuesday afternoon, as Wall Street shakes off a sluggish open amid a new wave of economic data. 
Via Talk Markets
Topics Stocks / Equities
Wall Street Inches Up Ahead Of Tariff Day: What's Driving Markets Tuesday?
Following the worst quarterly performance for U.S. stocks in over two years, caution dominated Wall Street as investors awaited details on the tariff plans expected from the Trump administration on... 
Via Benzinga
Topics Government World Trade
Exposures Political Tariff
These S&P500 stocks are gapping in today's session
Seeking insights into today's market movers? Discover the S&P500 gap up and gap down stocks in today's session on Tuesday. Stay informed about the latest market trends. 
Via Chartmill
Why Johnson & Johnson (JNJ) Shares Are Falling Today
Shares of multinational healthcare company Johnson & Johnson (NYSE:JNJ) fell 5.6% in the morning session after a judge in Texas rejected the company's third attempt to use bankruptcy as a legal shield... 
Via StockStory
Topics Bankruptcy Lawsuit
Exposures Financial Legal
US Manufacturing Slips Into Contraction As Tariff-Driven Costs Hit Near 3-Year High
The brief revival in U.S. factory activity vanished in March as input prices shot up at the fastest pace since mid-2022, raising red flags about eroding profit margins, cost pass-through risks and... 
Via Benzinga
These S&P500 stocks are moving in today's pre-market session
Pre-market stock analysis of S&P500 stocks on 2025-04-01: top gainers and losers in today's session. 
Via Chartmill
J&J Dives After Judge Tosses Out $10 Billion Talc-Based Bankruptcy Plan
The company says it will return to the civil court system to handle tens of thousands of claims its talc-based products caused cancer. 
Via Investor's Business Daily
Topics Bankruptcy Lawsuit
Exposures Financial Legal
US Judge Rejects Another Johnson & Johnson Attempt To Use Bankruptcy For Talc Cancer Claims
Johnson & Johnson will fight talc lawsuits in court after its subsidiary's bankruptcy plan was denied, reversing $7 billion in legal reserves. 
Via Benzinga
Topics Bankruptcy Lawsuit
Exposures Financial Legal
2 Value Stocks I'm Buying Right Now
Via The Motley Fool
Topics Economy
Exposures Interest Rates
Value Stocks Gain Ground As Inflation, Recession Fears Grow: 4 ETFs To Capitalize On The Trend
Value stocks are outperforming flashy growth rivals due to market uncertainty, making value-based ETFs a good bet for steady income and diversification. 
Via Benzinga
Topics ETFs Economy
Exposures Economy Interest Rates
1 Healthcare Stock to Target This Week and 2 to Turn Down
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
Exposures COVID-19 US Equities
Is Hims & Hers Stock Too Cheap to Pass Up?
This high-growth stock may be cheaper than you think. 
Via The Motley Fool
3 Relatively Safe Stocks to Buy Right Now
Via The Motley Fool
Topics Intellectual Property
Exposures COVID-19 Intellectual Property
Elliott Wave Technical Analysis: Johnson & Johnson - Friday, March 28
Looking for further upside into wave {v}, as we appear to be missing one leg higher to complete the five-wave move subdivision. 
Via Talk Markets
Topics Stocks / Equities
Investors Are Flocking to These 3 Vanguard Sector ETFs. Should You Buy Them Too?
Via The Motley Fool
Topics ETFs Economy Government
Exposures Economy Political Tariff
2 Reasons to Like JNJ and 1 to Stay Skeptical
Since September 2024, Johnson & Johnson has been in a holding pattern, posting a small return of 0.7% while floating around $163.19. 
Via StockStory
Topics Supply Chain
Exposures Supply Chain
What Rare Earth Minerals Does Ukraine Have?
Ukraine is recognized as a country with significant mineral wealth, including a variety of rare earth elements (REEs) and other critical minerals. These resources have drawn global attention,... 
Via MarketMinute
Topics Economy Electric Vehicles Emissions
Exposures Economy Electric Vehicles Fossil Fuels
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Uncertainty has cast a pall over medical stocks, which are taking a "wait-and-see" approach to Trump's tariffs. 
Via Investor's Business Daily
Topics Government
Exposures Political
2 Recession-Proof Dividend Stocks to Buy and Hold
Via The Motley Fool
J&J Drug Combo Outperforms Leading Lung Cancer Treatment In Survival Study
Johnson & Johnson's MARIPOSA study shows Rybrevant plus Lazcluze significantly extends overall survival in first-line EGFR-mutated NSCLC over osimertinib. 
Via Benzinga
Kenvue Stock In Focus As TOMS Capital Reportedly Pushes For Sale Or Breakup: Will It Shift Retail Mood?
Earlier this month, the company appointed three new directors, including Starboard Value CEO Jeffrey Smith, to its board as part of an agreement with the activist hedge fund after months of... 
Via Stocktwits
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
FDA Approves Johnson & Johnson's Tremfya For Crohn's Disease
Johnson & Johnson's Tremfya gains FDA approval for Crohn's disease, backed by Phase 3 trial data and demonstrating superiority over Stelara in key endpoints. 
Via Benzinga
Exposures Product Safety
Johnson & Johnson To Invest $55 Billion In US To Boost Manufacturing, Drug Discovery
Johnson & Johnson has announced a $55 billion investment in the U.S. over the next four years. This move will boost American manufacturing, research, and development, creating high-tech jobs and... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.